md1225, I called all that I know that have PPHM, and big positions. Most did nothing, 3 of them increased and NONE sold even 1 PPHM share.
Now these are INFORMED people so that may not be representative or comparable with the general public that is not and who you can make panic very easily.
We know Worsley was in talks with many BP's (global ones he said). These BP's understand 100% what is happening here with SUNRISE and will not even blink. They possibly ALL had some trials with unexpected control arm results.
If pre-deals would have been made they will have been made based on BAVITUXIMAB results out of SUNRISE. Following the IDMC advice and stop allows to unblind NOW and show results because PPHM KNOW FOR SURE that BAVITUXIMAB performed according trial expectations. It was in the PR so the IDMC must have provided that data otherwise PPHM could never have PRed that.
Those results will be compared to HISTORICAL by a BP (they are not bound to apply the FDA rules) because BP will NOT want to take the risk that a result is GOOD because the CONTROL ARM UNDERPERFORMED. They know the drug has it value if it improves on the historical max. of 10 months and that it is WORTHLESS if it would have beaten a poor 7 months control arm by setting down 10 months.
Of course by protecting themselves against under performing control arms they inherently protect PPHM against outperforming control arms.
And Dr. Briges article in Nature Magazine would FOR SURE have been stopped if there was something wrong with Bavituximab, it is mentioned 24 times in it. Editors have the means to put such article on hold, certainly that it was the PRELIMINARY version that they could have EASILY removed from the SMALL number of subscribers that have access to it before it becomes available for sale to the general public. Yet, they didn't, the article is still out there.
Market Data 
Markets 
AI
